news
Stiefel signs worldwide acquisition and license agreement for Toctino®
11 June 2012 | By GlaxoSmithKline
Stiefel has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd...
List view / Grid view
GlaxoSmithKline (GSK)
news
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
9 June 2012 | By GlaxoSmithKline
Detailed 52 and 32-week data from the first two Phase III studies...
news
GSK extends tender offer for all outstanding shares of Human Genome Sciences
8 June 2012 | By GlaxoSmithKline
GSK has extended its tender offer to acquire all of the outstanding shares of HGS...
article
Working independently or as part of a team: Which works best?
When I sat down to write this article, my immediate thought was about work styles. Is it better to work independently or in teams? Wouldn’t it be great to hear from someone on the ‘floor’ who has worked both in the lab and in the production environment? Work styles: independent…
article
Near Infrared supplement 2012
In this Near Infrared supplement: Understanding external factor influences and the right use of chemometrics; Recent advances in spectroscopic measurements applied to pharmaceutical testing; Discover what vendor companies are discussing in our Near Infrared Spectroscopy Leaders Roundtable...
article
Next generation antibody therapeutics: Antibody fragments, dual-targeting strategies, and beyond…
9 October 2009 | By Dr Martin Scott, Molecular Cell Biologist, Biopharm R&D, GlaxoSmithKline and Dr Neil Clarke, Molecular Cell Biologist and Biology Section Leader, Biopharm R&D, GlaxoSmithKline
A multitude of novel therapeutic antibody formats based on modification of the conventional IgG format have arisen in recent years. The intensification of interest in this area reflects a pressing need for an additional repertoire of therapeutic molecules which retain the exquisite binding specificity and low intrinsic toxicity of monoclonal…
article
Computational prediction of microRNA and targets
29 September 2008 | By Russell Grocock, Principle Bioinformatics Scientist, GSK
MicroRNAs (miRNAs) are small (~21nucleotides), evolutionarily conserved, noncoding RNA molecules that regulate gene expression1. In mammalian genomes, conservative predictions suggest that between 500-1500 miRNAs exist. There miRNAs appear to be capable of regulating the expression of multiple genes, with many genes appearing to be regulated by multiple, different, miRNAs2. Less…
